ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Gilead NASH drug fails late stage trial pharmaphorum
February 13, 2019Gilead’s top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a phase 3 trial. -
Phase 3 STELLAR-4 Study of Selonsertib Did Not Meet Primary Endpoint americanpharmaceuticalreview
February 13, 2019Gilead Sciences announced STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1).....
Pharma Sources Insight January 2025
